Espinosa-Franco B, García GML

Language: Spanish
References: 14
Page: 29-35
PDF size: 166.58 Kb.

ABSTRACT

It is known that all medicines can cause adverse reactions. This reactions rank from moderate to severe adverse reactions which can risk patient life. To detect the presence of adverse reactions of not inhaled drugs in hospitalized patients at a Chronic Obstructive Pulmonary Disease (COPD) clinic as well as severity and causality, a prospective and transversal study was performed from January to October of 2006. The patients were monitored from their admission to their egress, asking the patients, ckecking their clinical history and their nursery inform, making a daily diagnostic, treatment and potential adverse reactions registry. The adverse reaction definition proposed by WHO was used. Descriptive statistic was applied. Overall, 60 (29.4%) adverse drug reaction were detected in 204 hospitalized patients in this period. 65% were men and 35% were women with average age of 59.53 years and a 19 days average stay at hospital, with and average number of prescribed drugs of 9. The 46.7% with COPD (VEF1 40.12% y VEF1/CVF 61.93%), asthma 15%, pneumonia 8.3% and others. The implicated drugs were: methylprednisolone 26.67%, ceftriaxone 8.33%, ciprofloxacin 10% and heparin 11.67%. About the severity it was found that 7.14% were mild, 87.14% were moderately and 5.71% serious. It was found that a higher percentage of adverse reactions were developed in these patients than those reported at international level.

REFERENCES

1. Galleli L, Ferreri G, Colosimo M, Pirritano D, Guadagnino L, Pelaia G, Maselli R, De Sarro GB. Adverse drug reactions to antibiotics observed in two pulmonology divisions of Catanzaro, Italy: a six-year retrospective study. Pharmacological Research. 2002;46(5):395-400.

2. Meyboom RH, Egberts AC, Gribnau FW, Hekster YA. Pharmacovigilance in perspective. Drug Safety 1999; 21(6): 429-47.

3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalizad patients. A meta-analysis of prospective studies. JAMA 1998; 279(15):1200-5.

4. Comité de expertos: International drug monitoring: The role of national centers. Tech Rec Ser Nº 498. Ginebra. Organización Mundial de la Salud. 1972.

5. Dormann H, Muth-Selbach U, Krebs S, Criegee-Rieck M, Tegeder I, Schneider HT, Hahn EG, Levy M, Brune K, Geisslinger G. Incidence and costs of adverse drug reactions during hospitalisation. Drug Safety 2000; 22(2): 161-8.

6. Norma Oficial Mexicana NOM-220-SSA1-2002, Instalación y operación de la Farmacovigilancia. Diario Oficial de la Federación. 15 de noviembre 2004. México D.F.

7. Pfaffenbach G, Carvalho OM, Bergsten-Mendes G. Reacões adversas a medicamentos como determinantes da admissão hospitalar. Rev Assoc Med Bras 2002; 48(3): 237-41.

8. Mcdonnell P. Jacobs M. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002; 36: 1331-6.

9. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277(4):301-306.

10. Mc Donnell PJ. Turning adverse drug events into better patient care. [cited 2008 Feb]; [about 6 p.]. Available from: http://www.medscape. com/viewprogram/8715_index.

11. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug reactions. BMJ 1998;316:1295-8.

12. Thürmann PA. Methods and systems to detect adverse drug reactions in hospitals. Drug Safety 2001;24(13):961-8.

13. Van der Hooft CS, Sturkenboom MC, Grootheest KV, Kingma HJ, Stricker BH. Adverse drug reaction-related hospitalisations. Drug Safety 2006; 29(2): 161-8.

14. Corral B, Guerrero A, Beltrán G, Salas T. Utilización del CMBD como herramienta para la detección de acontecimientos adversos a medicamentos. Farm Hosp (Madrid) 2004; 28(4): 258-65.